PICU COVID-19 Intl. Collab -Epidemiology and Treatment of MIS-C by M.Levin et al | OPENPediatrics

This special version of the World Shared Practice Forum features speakers from the monthly International PICU COVID-19 Collaborative meeting hosted by Dr. Jeffrey Burns. This is a cutting-edge worldwide online collaboration in which the latest knowledge and best practices relating to COVID-19 are shared among front-line clinicians in real-time. In this session from September 8, 2020, clinicians review current international COVID-19 treatment practices data and take a deeper look into the epidemiology and treatment of MIS-C. Dr. Mike Levin discusses the influx of new literature surrounding MIS-C, followed by an expert panel discussion led by Drs. Jay Mehta and Lauren Henderson discussing MIS-C treatments based on these new and recent findings. Initial publication: October 26, 2020. OPENPediatrics attempts to keep all COVID-19 information as accurate and up to date as possible. However, as recommendations for care and treatment are rapidly changing due to the nature of the pandemic, Boston Children's Hospital does not assume any legal liability or responsibility for the accuracy, completeness or usefulness of any information on OPENPediatrics. We advise users to please pay close attention to the publication date of all COVID-19 content, and always adhere to your institution’s specific policies and guidelines. Please visit: www.openpediatrics.org OPENPediatrics™ is an interactive digital learning platform for healthcare clinicians sponsored by Boston Children's Hospital and in collaboration with the World Federation of Pediatric Intensive and Critical Care Societies. It is designed to promote the exchange of knowledge between healthcare providers around the world caring for critically ill children in all resource settings. The content includes internationally recognized experts teaching the full range of topics on the care of critically ill children. All content is peer-reviewed and open access-and thus at no expense to the user. For further information on how to enroll, please email: [email protected]